Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced new equity awards granted on December 31, 2024. The company issued 5,330 restricted stock units (RSUs) to one new employee under its 2024 Inducement Stock Incentive Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment. The RSUs will vest equally over four years, with annual installments beginning January 1, 2025, contingent on the employee's continued service with the company.
Verve Therapeutics, un'azienda in fase clinica focalizzata su medicinali genetici per le malattie cardiovascolari, ha annunciato nuove assegnazioni azionarie concesse il 31 dicembre 2024. L'azienda ha emesso 5.330 unità azionarie restrittive (RSUs) a un nuovo dipendente nell'ambito del suo Piano di Incentivazione Azionaria 2024. Questa concessione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) e funge da incentivo per l'occupazione. Le RSUs matureranno in modo uniforme nel corso di quattro anni, con rate annuali a partire dal 1° gennaio 2025, in base al servizio continuativo del dipendente con l'azienda.
Verve Therapeutics, una empresa en etapa clínica centrada en medicamentos genéticos para enfermedades cardiovasculares, ha anunciado nuevos premios en acciones otorgados el 31 de diciembre de 2024. La empresa emitió 5,330 unidades de acciones restringidas (RSUs) a un nuevo empleado bajo su Plan de Incentivo de Acciones por Inducción 2024. Esta concesión cumple con la Regla de Cotización de Nasdaq 5635(c)(4) y sirve como incentivo para el empleo. Las RSUs se consolidarán de manera equitativa durante cuatro años, con cuotas anuales que comenzarán el 1 de enero de 2025, dependiendo de la continuación del servicio del empleado con la empresa.
Verve Therapeutics는 심혈관 질환을 위한 유전자 치료제에 중점을 둔 임상 단계 회사로, 2024년 12월 31일에 부여된 새로운 주식 보상을 발표했습니다. 이 회사는 5,330개의 제한주식단위(RSU)를 2024년 유인 주식 인센티브 계획에 따라 새로운 직원에게 지급했습니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)를 준수하며 취업을 위한 유인으로 활용됩니다. RSU는 4년 동안 균등하게 취득됩니다, 2025년 1월 1일부터 시작되는 연간 지급이 직원의 회사 서비스 지속 여부에 따라 달라집니다.
Verve Therapeutics, une entreprise en phase clinique axée sur les médicaments génétiques pour les maladies cardiovasculaires, a annoncé de nouvelles attributions d'actions le 31 décembre 2024. L'entreprise a émis 5 330 unités d'actions restreintes (RSUs) à un nouvel employé dans le cadre de son Plan d'Incentive d'Actions 2024. Cette attribution est conforme à la Règle de Cotation Nasdaq 5635(c)(4) et sert d'incitatif à l'emploi. Les RSUs vont acquérir leurs droits de manière égale sur quatre ans, avec des versements annuels commençant le 1er janvier 2025, en fonction de la continuité du service de l'employé au sein de l'entreprise.
Verve Therapeutics, ein auf genetische Medikamente für Herz-Kreislauf-Erkrankungen fokussiertes Unternehmen in der klinischen Phase, hat neue Eigenkapitalvergaben am 31. Dezember 2024 angekündigt. Das Unternehmen hat 5.330 eingeschränkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter im Rahmen seines Aktien-Incentive-Programms 2024 vergeben. Diese Zuwendung erfüllt die Nasdaq-Listing-Regel 5635(c)(4) und dient als Anreiz für die Beschäftigung. Die RSUs werden über einen Zeitraum von vier Jahren gleichmäßig wertvoll, mit jährlichen Raten, die am 1. Januar 2025 beginnen, abhängig von der fortgesetzten Zugehörigkeit des Mitarbeiters zum Unternehmen.
- None.
- None.
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee’s continued service with the company on each such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
How many RSUs did Verve Therapeutics (VERV) grant in its December 2024 inducement award?
What is the vesting schedule for VERV's December 2024 inducement RSU grants?
Under which plan did Verve Therapeutics issue its December 2024 inducement grants?
When will the first vesting date occur for VERV's December 2024 inducement RSUs?
